A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-95266 in participants with relapsed and/or refractory multiple myeloma (R/R MM).
Multiple Myeloma
DRUG: CC-95266|DRUG: Fludarabine|DRUG: Cyclophosphamide|DRUG: Bendamustine
Number of participants with Adverse Events (AEs), Up to 2 years after CC-95266 infusion|Number of participants with significant laboratory abnormalities, Up to 2 years after CC-95266 infusion|Number of participants with Dose Limiting Toxicities (DLTs), Up to 2 years after CC-95266 infusion|Maximum Tolerated Dose (MTD), Up to 2 years after CC-95266 infusion|Recommended Phase 2 Dose (RP2D), Up to 2 years after CC-95266 infusion
Pharmacokinetics - Maximum plasma concentration of drug (Cmax), Up to 2 years after CC-95266 infusion|Pharmacokinetics - Time to peak (maximum) serum concentration (tmax), Up to 2 years after CC-95266 infusion|Pharmacokinetics - Area under the curve for days 1-29 after CC-95266 infusion (AUC1-29), Up to 2 years after CC-95266 infusion|Overall response rate (ORR), Up to 2 years after CC-95266 infusion|Complete response rate (CRR), Up to 2 years after CC-95266 infusion|Very good partial response (VGPR) or better, Up to 2 years after CC-95266 infusion|Duration of response (DOR), Up to 2 years after CC-95266 infusion|Duration of complete response (DOCR), Up to 2 years after CC-95266 infusion|Time to response (TTR), Up to 2 years after CC-95266 infusion|Time to complete response (TTCR), Up to 2 years after CC-95266 infusion|Progression-free survival (PFS), Up to 2 years after CC-95266 infusion|Overall survival (OS), Up to 2 years after CC-95266 infusion
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-95266 in participants with relapsed and/or refractory multiple myeloma (R/R MM).